---
title: "TD Cowen maintains Arcutis Biotherapeutics at Buy, raises price target to $40 from $35"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/304521590.md"
description: "TD Cowen maintained Arcutis Biotherapeutics at Buy and raised its price target to $40 from $35, a 14.3% increase.The price target implies an upside of 17.5% from the Nov 4 close of $34.05.Explore more price target data and ratings for Arcutis Biotherapeutics on the , and track all previous and future analyst recommendations in the dedicated News Flow.DisclaimerSelect reference data provided by Benzinga. This information is not a recommendation for what you should do personally and does not constitute investment advice."
datetime: "2026-11-05T20:41:34.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/304521590.md)
  - [en](https://longbridge.com/en/news/304521590.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/304521590.md)
generator: "portal-rs"
---

# TD Cowen maintains Arcutis Biotherapeutics at Buy, raises price target to $40 from $35

TD Cowen maintained Arcutis Biotherapeutics at Buy and raised its price target to $40 from $35, a 14.3% increase.

The price target implies an upside of 17.5% from the Nov 4 close of $34.05.

Explore more price target data and ratings for Arcutis Biotherapeutics on the , and track all previous and future analyst recommendations in the dedicated News Flow.

**Disclaimer**

Select reference data provided by Benzinga. This information is not a recommendation for what you should do personally and does not constitute investment advice.

### Related Stocks

- [ARQT.US](https://longbridge.com/en/quote/ARQT.US.md)

## Related News & Research

- [Arcutis' Zoryve cream reduces itch in infants with atopic dermatitis in trial](https://longbridge.com/en/news/305471947.md)
- [Will Infant Eczema Data Change Arcutis Biotherapeutics Stock Narrative](https://longbridge.com/en/news/305548928.md)
- [Arcutis Biotherapeutics Q3 product revenue rises 45% on ZORYVE demand](https://longbridge.com/en/news/304333377.md)
- [Arcutis Begins Phase 3 Trial of Zoryve Cream 0.3% for Moderate to Severe Atopic Dermatitis](https://longbridge.com/en/news/304459505.md)
- [Cantor Fitzgerald initiates coverage of Arcutis Biotherapeutics with Overweight rating, $48 price target](https://longbridge.com/en/news/301963556.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**